A Phase 2 interventional study of Paragon Novel Metabolic Regulator (PNMR) and Dietary and Lifestyle Recommendations in Long COVID, sponsored by ParagonClinicals Inc.. Recruiting at 4 sites in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by ParagonClinicals Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada — 14 open to participants now, 17 under way, 3 of them phase 3. Post-Acute COVID-19 Syndrome · Canada.
Among the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada, this one is the 17th largest by planned enrollment of the 33 interventional ones that give a count, is one of 5 that started in 2026, is one of 3 in phase 2, reaches primary completion later than 5 of the 16 other live ones, and was the 40th registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →14 of the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada are open now. Recruiting first, the newest first:
York University · Sites in Canada
Ages 18–65
Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
University of Alberta · Sites in Canada
Ages 18+
Douglas D. Fraser · Sites in Canada, United States, Brazil and 4 more countries
Ages 18–65
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 5 · Phase 4 1
First in 2021; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 82 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 82 across the 33 interventional studies, 120 across the 7 observational. Of the 20 that completed or were terminated, 2 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 40 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with ParagonClinicals Inc. as lead sponsor.
ParagonClinicals Inc. has 1 study filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Post-Acute COVID-19 Syndrome with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07374562Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-QuébecStellate Ganglion Block for Long COVID Symptoms: A Randomized Controlled Trial | 2027-02 |
| NCT04736732Emilia Falcone, MDInstitut de Recherche Cliniques de Montreal (IRCM) Post-COVID-19 (IPCO) Research Clinic | 2027-05-04 |
| NCT07312409York UniversityDoes Taurine Supplementation Improve Vascular Function and Orthostatic Responses in Long COVID? | 2027-06-30 |
| NCT06082518Sunnybrook Health Sciences CentreImproving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This will be a six-week, randomized, parallel, two group, open-label design. Patients will be treated with Paragon Novel Metabolic Regulator (PNMR) + standard of care (SOC) or SOC alone for 6 weeks for the treatment of Long COVID. All patients will also be provided with with Dietary \& Lifestyle recommendations specifically designed to enhance immune system function and reduce viral proliferation.
Patients will be assessed in the clinic at screening/baseline, 3 and 6 weeks while on treatment, and by telephone at 4 weeks post-treatment.
All patients will be asked to fill in a diary to record their daily treatment dosage when being treated with PNMR + SOC or with SOC alone. Primary objective: To evaluate the efficacy of PNMR + (SOC) vs. SOC in the treatment and management of patients with long COVID.
Because:
And because metabolic research shows:
This is why the Dietary and Lifestyle Recommendations, which have been demonstrated by peer-reviewed research to benefit those with chronic viral infections causing mitochondrial \& immune system dysfunction, are being provided to both the control \& treatment groups in the trial. This gives both patient groups in the trial potential mechanisms for healing.
And while initial medical case studies indicate the ingredients in the PNMR potentially represent a powerful curative treatment for the chronic tissue \& organ damage many long COVID patients have, effective dietary \& lifestyle measures are critical to further accelerating this healing process.
Inclusion Criteria: The patient must meet all the following criteria to be enrolled in the study:
For women of involved in any sexual intercourse that could lead to pregnancy: Negative pregnancy test and willingness to use (consistent with local regulations) during the study period. Approved contraceptive methods include contraceptive pills or patches, hormonal implants, intrauterine device (IUD), diaphragm or cervical cap with spermicide, and condos with spermicide.
Note: If participant become pregnant during the study, they must stop taking the study products immediately and inform the study investigator.
Exclusion Criteria:
Any patient for whom vitamin D3 (cholecalciferol) is per the following patient situations:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in Group 1 are instructed to take 2 PNMR packs on Day 1 and evaluate and adjust their daily PNMR dosage from Day 2 to Day 42 of their 6-week treatment period up to a maximum of 6 packs per day based on the presence of long COVID symptoms. Patients lower the dosage by 1 pack /day based upon signals showing the body is healing (and has replenished its depleted sulfur protein nutrient stores - required for energy production and healing), as seen with a temporary release of sulfur-smelling flatulence, or rarely unpleasant dreams, if the patient no longer needs as much medicine. Patients maintain a minimum dosage of no less than 1 pack per 2 days. Patients are instructed to take PNMR 5-20 minutes before eating, 3-6 capsules at a time, with water. Patients in Group 1 are also given specific dietary and lifestyle recommendations. Patients receiving PNMR will additionally be treated with SOC as per the regional guidelines and the decision of the treating physician.
Drug: Paragon Novel Metabolic Regulator (PNMR) · Other: Dietary and Lifestyle Recommendations
Patients in Group 2 will be given specific dietary and lifestyle recommendations. Patients receiving PNMR will additionally be treated with SOC as per the regional guidelines and the decision of the treating physician.
Other: Dietary and Lifestyle Recommendations
Research shows human cell systems maintain significant cellular storage levels of a wide range of critical metabolites supporting enzymes driving mitochondrial and immune system function and healing, all of which can be depleted by serious illness. Such cell systems and components (including the cytosol, mitochondria, metabolic pathways within cells, white blood cells, antibodies, antimicrobial peptides, enzymes, and other compounds) require specific concentrations of specific amino and fatty acids - and corresponding concentrations of a wide range of specific metabolites - that together enable their continuous metabolism within those cell systems. The PNMR capsules (provided in 1 - 6 packets per day) are designed to quickly restore optimum and balanced cellular storage levels of those critical metabolites driving the balanced intracellular enzyme activity and metabolism required to maintain mitochondrial and immune system function, healing, and homeostatic regulation.
Dietary and Lifestyle Recommendations specifically designed to enhance immune system function and reduce viral proliferation
Change in distance walked on the 6-minute walk test (6MWT) after 6 weeks of treatment.
Patient baseline is first assessed at Day 0 upon screening, and then retested after 6 weeks of treatment.
Time frame: From enrollment to the end of treatment at 6 weeks
Change in distance walked on the 6MWT after 3 weeks of treatment.
Time frame: From enrollment to the completion of 3 weeks initial treatment.
Proportion of patients achieving an improvement of 30 meters or more on the 6MWT by 3 and 6 weeks on treatment.
Time frame: From enrollment to measurements made at 3 and 6 weeks
Time to achieving an improvement of 30 m or more on the 6MWT by 6 weeks on treatment.
Time frame: From enrollment to measurements made at either 3 or 6 week if achieved
Change in patient-reported assessment of fatigue on a 100 mm visual analogue scale (VAS) at 3 and 6 weeks on treatment.
Fatigue Severity over the last 7 days, reported on a 100 mm Visual Analogue Scale: 0 - 100, higher score means a worse outcome
Time frame: From enrollment assessment to assessments made at 3 and 6 weeks
Change in patient-reported assessment of brain fog duration at 3 and 6 weeks on treatment.
Brain Fog Duration seen over last 7 days: 0 - 7 days, higher score means a worse outcome
Time frame: From enrollment assessment to assessments made at 3 and 6 weeks
Change in patient-reported assessment of brain fog severity on a 100 mm VAS at 3 and 6 weeks on treatment.
Brain Fog Severity over the last 7 days reported on a 100 mm Visual Analogue Scale: 0 - 100, higher score means a worse outcome
Time frame: From enrollment assessment to assessments made at 3 and 6 weeks
Change in QoL as measured by the Medical Outcomes Study Short Form 36 (SF-36) at 3 and 6 weeks on treatment.
The SF-36 (Short Form 36) is a self-reported survey that measures 36 individual health-related indicators of Quality of Life (QOL). It asks the patient to rate their: General Health; General Health now compared to one week ago; along with more detailed evaluations of Physical Health, Role Limitations (Physical), Emotional Health, Role Limitations (Emotional), Social Functioning; and to rate other factors related to Pain, Energy, and Mood as compared to the week prior. Each question has a unique set of answers specific to the question. For some questions a higher score means a worse outcome, whereas for other questions a higher score means a better outcome. This method requires that the patient think through each answer individually.
Time frame: From enrollment measurement to measurements made at 3 and 6 weeks
Health care utilization at 3 and 6 weeks on treatment.
Health care utilization at 3 and 6 weeks on treatment. * Physician visits * Clinic visits * Other health care professional visits and consultations * Prescription medication use for the management of flu or flu-like illness * Non-prescription medication use for the management of flu or flu-like illness
Time frame: Health care utilization measured at 3 and 6 weeks on treatment.
Number of treatment-emergent adverse events (TEAEs) and serious TEAEs.
Time frame: Realized from enrollment to completion of treatment at 6 weeks
Plan to share: Yes — All IPD that underlie results in a publication.
Supporting information: Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Beginning 3 months and ending 3 years after the publication of results
Started May 2026 (actual). Primary completion is estimated for Aug 2026, 3 months after the start.
Of 63 phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's planned 3 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →